Research Article: Significance of Self-Injectable Biologics in Japanese Patients with Severe Allergic Diseases: Focusing on Pen-Type Devices and Copayment
Introduction:
The major barriers to continued treatment with biologics are usability, efficacy, adverse events, cost of care, and the need for hospital visits. Of these, drug efficacy and adverse events require medical monitoring. However, other important factors that are likely to affect patient compliance include the ease of use and amount of copayment. Five biologics have been approved for the treatment of severe asthma in Japan: omalizumab, an anti-IgE antibody; mepolizumab, an anti-interleukin (IL)- antibody; benralizumab,…
Read more